AbCellera Biologics (ABCL) PT Lowered to $49 at Credit Suisse
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.43 -1.21%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $49.00 (from $51.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
- Equity Bancshares (EQBK) PT Raised to $54 at DA Davidson
- Equity Bancshares (EQBK) PT Raised to $59 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
